Your browser doesn't support javascript.
loading
Early Gastric Cancers in Central Norway 2001 to 2016-A Population-Based Study.
Kvamme, Camilla J; Stillingen, Thomas L; Sandø, Alina D; Mjønes, Patricia; Bringeland, Erling A; Fossmark, Reidar.
Afiliação
  • Kvamme CJ; Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway.
  • Stillingen TL; Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway.
  • Sandø AD; Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway.
  • Mjønes P; Department of Gastrointestinal Surgery, St. Olav's Hospital, Trondheim University Hospital, 7030 Trondheim, Norway.
  • Bringeland EA; Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway.
  • Fossmark R; Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, 7030 Trondheim, Norway.
Cancers (Basel) ; 16(6)2024 Mar 20.
Article em En | MEDLINE | ID: mdl-38539555
ABSTRACT
Early gastric cancers (EGCs) are confined to the gastric mucosa and submucosa irrespective of lymph node metastases and constitute only a minor proportion of gastric cancer in Western countries. We aimed to characterize EGCs and assess the survival of EGC in Central Norway during 2001-2016. A retrospective population-based study on 1205 patients with gastric cancer was performed. At the time, surgical resection was the standard treatment, and 88 (7.3%) EGCs were identified. Histopathological specimens were re-examined, and the eCura score and survival were evaluated. The number of gastric cancers declined (p = 0.010), but the relative proportion of EGC was unchanged during the study period. EGCs were more often of the Lauren intestinal type (p < 0.001) compared with controls. A significant proportion (9.4%, n = 5) of the patients with a low-risk eCura had lymph node metastases, whereas further exclusion of tumors with histological ulceration or SM2 invasion identified an N0 cohort. The median survival for EGC patients was 117.1 months (95% CI 99.8-134.3) and the 5-year overall survival was 75%. Twelve deaths were cancer-related, either due to postoperative complications (5.7%, n = 5) or cancer recurrence (8%, n = 7). In conclusion, EGCs constituted a minor but constant proportion of gastric cancers. eCura alone was insufficient in predicting patients with pN0 disease.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega